SAREPTA THERAPEUTICS INC - DBCV 1.500%11/1 Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2018 to Q4 2024

Type / Class
Debt / DBCV 1.500%11/1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of SAREPTA THERAPEUTICS INC - DBCV 1.500%11/1 across Reporting Periods

Period Principal Value Change Price (% of par) (Median) Investors
2024 Q4 $0 $0 -$100,750,179 0
2024 Q3 $59,110,000 $100,871,202 -$98,810 170.36% 17
2024 Q2 $58,808,000 $126,974,286 -$1,890,787 215.49% 17
2024 Q1 $62,128,000 $111,135,462 -$643,332 178.69% 19
2023 Q4 $63,109,300 $89,439,554 -$2,413,220 141.5% 23
2023 Q3 $63,412,300 $112,893,938 +$748,602 176.98% 20
2023 Q2 $63,588,000 $108,032,901 +$10,156,096 168.73% 24
2023 Q1 $55,585,000 $107,801,451 -$599,358,216 193.58% 24
2022 Q4 $375,153,898 $701,172,724 -$3,591,848 186.81% 39
2022 Q3 $383,050,000 $639,662,553 -$152,632,017 166.9% 39
2022 Q2 $513,091,000 $646,800,148 -$50,844,369 125.89% 37
2022 Q1 $550,371,000 $724,392,310 +$4,273,670 131.29% 39
2021 Q4 $553,703,000 $810,954,622 -$3,830,280 146.45% 37
2021 Q3 $557,542,000 $828,388,343 +$15,911,788 148.13% 43
2021 Q2 $544,016,000 $719,711,018 -$16,204,729 132.06% 40
2021 Q1 $559,256,000 $731,288,641 -$104,428,693 130.73% 40
2020 Q4 $537,649,000 $1,320,300,217 +$13,320,822 245.14% 46
2020 Q3 $527,750,000 $1,094,833,197 +$33,594,245 207.35% 42
2020 Q2 $509,419,000 $1,173,397,315 +$4,020,127 229.75% 45
2020 Q1 $520,932,000 $800,781,398 +$3,182,461 152.04% 42
2019 Q4 $510,749,000 $1,011,767,770 +$19,580,624 194.64% 39
2019 Q3 $535,973,000 $710,004,016 +$27,271,973 132.16% 38
2019 Q2 $501,601,000 $1,115,753,662 -$55,546,054 222.59% 43
2019 Q1 $520,667,000 $940,831,000 +$860,869,000 180.49% 39
2018 Q4 $44,113,000 $73,926,000 +$73,926,000 167.58% 1